Does Earlier Thymectomy in Myasthenia Gravis Reduce the Corticosteroid Burden That Follows It?
A single patient, four months into a generalized myasthenia gravis diagnosis with his steroid response already plateauing. The disagreement isn't about whether thymectomy helps — a randomized trial already answered that — it's about when.
D.O., a 29-year-old warehouse operations manager, was diagnosed with generalized myasthenia gravis four months ago after a shift spent unable to keep his eyelids from drooping over inventory sheets, a job that already asks his shoulders and forearms for repetitive overhead reaching most of every shift. Antibody testing confirmed AChR-positive disease, and imaging found no thymoma — a relief at the time, though it turns out not to close the surgical question the way he assumed it would. Pyridostigmine gave him partial relief, and prednisone, now at 30 milligrams daily, brought his MG-ADL score down from 9 to 5, but his improvement has plateaued over the past six weeks, and nobody on the team is eager to keep pushing his steroid dose upward indefinitely to chase the remaining symptoms, especially with a physically demanding job still depending on his stamina holding through an eight-hour shift.
What actually moves the conversation is not whether surgery might help — MGTX, the randomized trial that settled this for non-thymomatous AChR-positive MG, already answered that in 2016 — but when. MGTX enrolled patients within five years of diagnosis, close to D.O.'s own timeline, and found that thymectomy combined with prednisone produced a significantly lower time-weighted average prednisone dose over three years than prednisone alone, along with less need for additional immunosuppressive drugs. The trial's own extended follow-up data suggest that benefit holds up years later. What it doesn't settle cleanly is whether operating now, at four months, meaningfully outperforms operating at ten months of optimized medical therapy first — the actual question in front of the team, framed on steroid exposure rather than the surgery itself.
When, not whether, framed on steroid exposure
I'd proceed to thymectomy now. MGTX gave us randomized evidence that thymectomy plus prednisone beats prednisone alone on the exact endpoint we're worried about — time-weighted steroid dose over three years — and D.O.'s profile matches that trial's population closely: young, AChR-positive, non-thymomatous, within five years of diagnosis, low surgical risk. If earlier intervention means more steroid-years avoided over his lifetime, waiting doesn't obviously buy him anything, and it delays a benefit MGTX already demonstrated.
MGTX's result is real and I'm not questioning the trial. But it's an average benefit across a randomized population, not a guarantee for any specific patient — some fraction of MGTX's medical-therapy-alone arm presumably did reasonably well without surgery, and we don't have D.O.'s individual probability of being one of them. His perioperative risk is genuinely low, I'll grant that, but avoiding an operation entirely, if optimized medical therapy can get him there, is a real, valid outcome worth actually trying for before committing him to surgery he might not have needed.
Framing this as "surgery already proved superior, so waiting buys nothing" treats MGTX's population-level average as if it applies uniformly to every enrolled-profile-matching patient individually, which isn't what an averaged trial result actually licenses.
I'd frame this around his steroid-burden trajectory rather than a fixed calendar date, since that's actually what MGTX's own primary endpoint measured. His MG-ADL improvement has already plateaued at 30 milligrams of prednisone — that's a real signal, not an arbitrary six-week mark. I'd give him a bounded window, roughly two more months, with pyridostigmine optimized and prednisone held rather than pushed higher.
If his steroid requirement is still climbing or his function hasn't improved further by then, that's the trigger to proceed to thymectomy without further delay — using his own trajectory as the decision point rather than either operating immediately or deferring indefinitely on medical-therapy hope alone.
Agreed: a two-month bounded trial of optimized pyridostigmine with prednisone held flat, steroid requirement and MG-ADL tracked explicitly as the trigger for thymectomy if either fails to improve.
Not agreed: the Neurologist's underlying position that earlier surgery straightforwardly maximizes lifetime steroid-years avoided remains unresolved — the team proceeded with the bounded trial as a compromise, not because that position was judged wrong.